Merck & Co./$MRK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
- Ticker
- $MRK
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 74,000
- Headquarters
- Rahway, United States
- Website
- www.merck.com
Merck & Co. Metrics
BasicAdvanced
$356B
146.10
$0.99
0.12
$3.40
2.35%
Price and volume
Market cap
$356B
Beta
0.12
52-week high
$156.92
52-week low
$92.11
Average daily volume
9.5M
Dividend rate
$3.40
Financial strength
Current ratio
1.352
Quick ratio
0.809
Long term debt to equity
1.108
Total debt to equity
1.199
Dividend payout ratio (TTM)
341.05%
Interest coverage (TTM)
12.08%
Profitability
EBITDA (TTM)
15,964
Gross margin (TTM)
76.91%
Net profit margin (TTM)
3.64%
Operating margin (TTM)
35.16%
Effective tax rate (TTM)
48.57%
Revenue per employee (TTM)
$910,000
Management effectiveness
Return on assets (TTM)
11.29%
Return on equity (TTM)
5.06%
Valuation
Price to earnings (TTM)
146.102
Price to revenue (TTM)
5.303
Price to book
7.94
Price to tangible book (TTM)
-77.07
Price to free cash flow (TTM)
24.232
Free cash flow yield (TTM)
4.13%
Free cash flow per share (TTM)
5.962
Dividend yield (TTM)
2.35%
Forward dividend yield
2.35%
Growth
Revenue change (TTM)
4.89%
Earnings per share change (TTM)
-86.93%
3-year revenue growth (CAGR)
4.34%
10-year revenue growth (CAGR)
5.38%
3-year earnings per share growth (CAGR)
-18.11%
10-year earnings per share growth (CAGR)
-6.60%
3-year dividend per share growth (CAGR)
5.27%
10-year dividend per share growth (CAGR)
6.26%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Analyst projections of the future price of Merck & Co. stock.
Bulls say / Bears say
Merck’s third-quarter sales and adjusted earnings beat expectations, and it raised the lower end of its 2026 sales forecast. This points to continued near-term operating strength. (Reuters)
Newer products are gaining scale: Winrevair sales rose 93% to $694 million, while the under-the-skin Keytruda QLEX generated $830 million in the quarter. Their growth could help broaden Merck’s revenue base. (Merck)
The pipeline has produced encouraging late-stage cancer data: intismeran plus Keytruda cut the risk of melanoma recurrence or death by 42%, and sac-TMT showed a survival benefit in endometrial cancer. These programmes could add future growth opportunities, although further development and approvals remain necessary. (Merck, Merck)
Merck remains heavily reliant on Keytruda, whose key patent protections are due to start expiring in 2028. Reuters also reports that Keytruda’s growth is expected to moderate as it approaches peak sales in some uses. (Reuters)
Some of the latest sales strength may reflect timing rather than lasting demand: Merck said about $550 million of third-quarter growth came from purchases made earlier than expected. Gardasil’s rebound also benefited from early US government buying, while demand in China has remained weak. (Reuters)
Merck and Daiichi Sankyo withdrew their US filing for cancer drug I-DXd after the FDA said the submitted data were not enough to support accelerated approval. That delays a potential launch and return on a major development partnership. (Fierce Biotech)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Merck & Co. News
AllArticlesVideos

Merck stops trials of blood cancer drug after risk assessment
Reuters6 hours ago

Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
Business Wire6 hours ago

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Business Wire5 days ago
Funds containing Merck & Co.
AllUSDEURGBP
Fund name | Fund size | $MRK weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector£XLVP | $552M | 5.90% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 5.90% |
iShares S&P 500 Health Care Sector€IUHE | €134M | 5.33% |
SPDR MSCI World Health Care£HEAW | $708M | 3.93% |
SPDR MSCI World Health Care$WHEA | $708M | 3.93% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.